NAVAN Technologies utilizes NanoStraws for non-perturbative delivery of various cargo types into primary cells, enhancing cell viability and function. This technology addresses the manufacturing challenges of vector-based cell and gene therapies, enabling the development of effective treatments across a wide range of medical indications.
Funding
Funding not disclosed
Founders
Product
Problem
Current vector-based methods for cell and gene therapy face manufacturing challenges, including limitations in cargo delivery into primary cells, which can compromise cell viability and function. This restricts the development of effective treatments for a wide range of medical indications.
Solution
NAVAN Technologies employs NanoStraws, a physical conduit for intracellular access, to enable non-perturbative delivery of diverse cargo types into primary cells. This approach enhances cell viability and function by providing a gentle and precise method for transporting materials into and out of cells. NAVAN's technology facilitates efficacious dosage control, multiplexing, and even cellular extraction/sampling. By overcoming the limitations of viral-based and electroporation-based cell manufacturing, NAVAN aims to accelerate the development of cell and gene therapies and regenerative medicines.
Target Audience
NAVAN's primary customers are researchers and companies involved in cell and gene therapy development, as well as those working in regenerative medicine.
Features
- NanoStraws technology provides a physical, non-perturbative conduit for delivery into and out of cells.
- Enables transport of virtually all cargo types into virtually all primary cell types.
- Preserves cell health and function during delivery.
- Facilitates efficacious dosage control and multiplexing.
- Supports cellular extraction and sampling.
- Offers an alternative to viral-based and electroporation-based cell manufacturing.